A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
Status unknown · Phase 1 · NCT03557619
Conditions: Hematologic Malignancies
At a glance
- Research payments reported, 2025
- $2,500
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 12
About the trial
- Sponsor
- AbbVie
- Tested
- Venetoclax (drug), ethinyl estradiol/levonorgestrel (drug)
- Dates
- Started 2019-07-30; completion 2026-03-21
- Results posted
- Not yet
A study to assess the effect of multiple doses of venetoclax on the pharmacokinetics of ethinyl estradiol and levonorgestrel in female participants with different hematological malignancies. Upon completion of this study, participants receiving clinical benefit in the opinion of the investigator and without any clinically significant evidence of disease progression with no access to venetoclax (not approved for the treated indication) may continue receiving venetoclax at the discretion of the investigator in a separate extension study.
From ClinicalTrials.gov, last updated 2024-08-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $2,500 in research payments for this study in 2025 (1 payments).
Products named: Venclexta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dartmouth-Hitchcock Medical Center $2,500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.